NDARECTALSUPPOSITORY
Approved
May 1958
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
PHENERGAN (promethazine hydrochloride) by Teva is clinical pharmacology promethazine is a phenothiazine derivative which differs structurally from the antipsychotic phenothiazines by the presence of a branched side chain and no ring substitution. First approved in 1958.
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PHENERGAN (promethazine hydrochloride) is a first-generation phenothiazine derivative functioning as an H1 receptor antagonist with secondary sedative and antiemetic properties. It is indicated for allergic reactions, nausea/vomiting, and sedation across multiple routes of administration. The drug works through histamine receptor blockade with minimal dopamine antagonism compared to other phenothiazines.
LOE Approaching
As a mature, off-patent asset approaching end-of-life, the product likely operates with a lean commercial infrastructure focused on market maintenance rather than growth.
Mechanism of Action
CLINICAL PHARMACOLOGY Promethazine is a phenothiazine derivative which differs structurally from the antipsychotic phenothiazines by the presence of a branched side chain and no ring substitution. It is thought that this configuration is responsible for its relative lack (1/10 that of…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PHENERGAN represents a career opportunity in product lifecycle management and mature brand stewardship, ideal for professionals seeking to optimize profitability and market position in a stable, low-growth asset. Limited opportunity for innovation-focused roles; emphasis is on efficiency, cost control, and customer retention.
Worked on PHENERGAN at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.